Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Latest Information Update: 28 Jun 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Carcinoma; Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms A-BRAVE; A-BRAVE Trial
- 04 Jun 2024 Results (n=477) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results presented in the American society for clinical oncology Media Release.
- 30 Oct 2023 Planned End Date changed from 1 Jun 2023 to 1 Oct 2025.